Exploring a Milestone-Based Approach as an Outcome Measure for Disease-Modifying Parkinson Disease Trials
Objective: To replicate a composite milestone(CM) approach in a range of Parkinson Disease(PD) studies(observational, clinical trials) over a long time period(up to 12 years). To…Assessing an inclusive online lifestyle-based intervention program that supports British Columbians living with chronic neurological conditions, their care partners and healthy agers
Objective: To evaluate the implementation, feasibility, and perceived benefits of the BC Brain Wellness Program (BCBWP), an interdisciplinary lifestyle-based intervention designed to support the quality of…Patient-Defined Disease Progression in Parkinson Disease: Towards Patient-Relevant Outcome Measures
Objective: To carry out a survey on a representative sample of people with Parkinson’s (PwP) about their lived experience of a comprehensive list of Parkinson…Move-Brain-PD: a Randomized Multicenter Protocol of Remotely Monitored Home-based Aerobic Exercise for Parkinson’s Disease Patients with Mild Cognitive Impairment
Objective: To describe the rationale and design of Move-Brain-PD, a randomized multicenter study evaluating whether remotely monitored home-based aerobic exercise improves cognition and motor symptoms…Clinical and Genetic Profile of the ACTIVATE Population: A Phase 2 Trial of BIA 28-6156 in GBA-PD
Objective: To characterize the patient population enrolled in the ACTIVATE study, a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, tolerability, pharmacodynamics,…Prospective Comparison of Volumetric and Diffusion MRI Biomarkers for Multiple System Atrophy
Objective: We aimed to develop new imaging biomarkers allowing objective monitoring of early Multiple System Atrophy (MSA) progression, which could improve outcome definition for future…Physical Activity is Associated with Attenuated Motor and Cognitive Progression in Parkinson’s Disease
Objective: To determine whether physical activity (PA) modifies the rate of motor and cognitive progression in Parkinson’s disease (PD) and to identify specific components of…Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa–Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson’s Disease
Objective: To describe indications and short-term outcomes of FLC/FCD in PD patients previously treated with DBS and/or LCIG. Background: Advanced Parkinson's disease patients treated with…A Phase 1b Study to Investigate Safety, Tolerability and Biomarker Responses of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease
Objective: The aim of this study was to investigate safety, tolerability and biomarker responses of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s…Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases
Objective: To describe inpatient titration methodology, dosing parameters, support services utilization, and early challenges in consecutive advanced PD patients. Background: Successful implementation of continuous subcutaneous…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »